Apremilast for Erythema Multiforme

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

January 13, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Erythema Multiforme
Interventions
DRUG

Apremilast

Apremilast (Otezla), oral medication Day 1: 10 mg in the morning. Day 2: 10 mg in the morning and 10 mg in the evening. Day 3: 10 mg in the morning and 20 mg in the evening. Day 4: 20 mg in the morning and 20 mg in the evening. Day 5: 20 mg in the morning and 30 mg in the evening Day 6: 30 mg twice daily Maintenance dosing: 30 mg twice daily

Trial Locations (1)

19104

Perelman Center For Advanced Medicine, Philadelphia

All Listed Sponsors
lead

Robert Micheletti

OTHER